Fab-scFv fusion protein: An efficient approach to production of bispecific antibody fragments

Journal of Immunological Methods

Volumn 267, Issue 2, 2002, Pages 213-226

  Lu, Dan ^a   Jimenez, Xenia ^a   Zhang, Haifan ^a   Bohlen, Peter ^a   Witte, Larry ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Angiogenesis; Antibody engineering; Bispecific antibody; Endothelial cells; Fab scFv; Fusion protein; KDR Flt 1; VEGF PlGF

Indexed keywords

BISPECIFIC ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS LINKING; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION;

ANIMALS; ANTIBODIES, BISPECIFIC; CELL DIVISION; CELL LINE; CELL MOVEMENT; DRUG DESIGN; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FRAGMENTS; KINETICS; LYMPHOKINES; MICE; PREGNANCY PROTEINS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

ESCHERICHIA COLI;

EID: 0037106007     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(02)00148-5     Document Type: Article

References (33)

1. Bispecific antibodies as novel bioconjugates
2. Bispecific human IgG by design
3. Toward the production of bispecific antibody fragments for clinical applications
4. Design and production of novel tetravalent bispecific antibodies
5. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library
6. Autocrine stimulation of VEGFR-2 activates human leukemia cell growth and migration
7. Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris
8. "Diabodies": Small bivalent and bispecific antibody fragments
9. High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions
10. Formation of a bispecific antibody by the use of leucine zippers
11. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2
12. Identification of residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies
13. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor
14. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity
15. Construction, expression, and activity of a bivalent bispecific single-chain antibody
16. An efficient route to human bispecific IgG
17. The first constant domain [C(H)1 and C(L)] of an antibody used as heterodimerization domain for bispecific miniantibodies
18. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli
19. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli
20. New protein engineering approaches to multivalent and bispecific antibody fragments
21. H3 domains for heavy chain heterodimerization
22. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives
23. Introduction: Bispecific antibodies
24. Bispecific monoclonal antibodies from hybrid hybridomas
25. Design and application of diabodies, triabodies, and tetrabodies for cancer targeting
26. Immunotherapeutic perspective for bispecific antibodies
27. Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins
28. 2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity
29. HER2 overexpressing tumor cells
30. High level secretion of a humanized bispecific diabody from Escherichia coli
31. Remodeling domain interfaces to enhance heterodimer formation
32. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single chain antibodies from a phage display library
33. An efficient route to the production of an IgG-like bispecific antibody